This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SH2 | |
|---|---|
| Name | SH2 |
SH2 SH2 domains are ~100 amino acid protein interaction modules that recognize phosphorylated tyrosines and mediate modular assembly in signaling networks. First characterized in studies linking receptor tyrosine kinases to downstream effectors, SH2 domains appear in enzymes, adaptors, and scaffold proteins across metazoans and unicellular eukaryotes. Their precise phosphopeptide selectivity underlies roles in pathways studied by investigators at institutions such as Harvard University, Cold Spring Harbor Laboratory, Massachusetts Institute of Technology, Stanford University, and University of Cambridge.
SH2 domains were discovered during biochemical and genetic analyses of linkages between phosphotyrosine residues and downstream effectors in research programs at National Institutes of Health and industrial labs like Pfizer and GlaxoSmithKline. Seminal work by groups including those of Tony Pawson, Jonker, and Tony Hunter established the principles of phosphotyrosine recognition that connect to studies at Salk Institute, Wellcome Trust, Max Planck Society, Columbia University, and University of California, San Francisco. SH2-containing proteins such as GRB2, Src family kinases, PI3K regulatory subunits, SHC1, CRK, and PLCγ illustrate the domain's prevalence in diverse signaling assemblages examined in projects funded by organizations like Wellcome Trust and European Research Council.
SH2 domains adopt a conserved compact fold revealed by structural biology groups at European Molecular Biology Laboratory, Rutherford Appleton Laboratory, Yale University, University of Oxford, and ETH Zurich. High-resolution structures determined by teams at Brookhaven National Laboratory and Lawrence Berkeley National Laboratory show a central β-sheet flanked by α-helices, forming a pocket that engages phosphotyrosine residues. Crystallographic and NMR efforts involving investigators from Imperial College London, Johns Hopkins University, University of Toronto, McGill University, and University of Melbourne identified specificity determinants that recognize residues C-terminal to phosphotyrosine, explaining selectivity differences between domains in proteins such as Src, Fyn, Yes, Lyn, p85α, and Vav. Mutagenesis and peptide-library screening in labs at Cold Spring Harbor Laboratory and University of Pennsylvania mapped binding motifs, informing computational predictors developed at Carnegie Mellon University and California Institute of Technology.
SH2-mediated interactions coordinate signaling cascades central to growth factor responses studied in contexts including Epidermal Growth Factor Receptor research, Insulin Receptor signaling, and T-cell receptor activation. Adapter proteins with SH2 domains, exemplified by GRB2 and SHC1, link phosphorylated receptors to effectors like RAS-MAPK modules characterized in labs at University College London and Cold Spring Harbor Laboratory. PI3K regulatory subunits containing SH2 domains couple to receptors to activate AKT signaling, a pathway investigated by groups at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Johns Hopkins University School of Medicine. Studies in immunology at National Institute of Allergy and Infectious Diseases and Pasteur Institute detail SH2 roles in leukocyte activation mediated by proteins such as SHP2 and ZAP-70.
Dysregulation of SH2-containing proteins contributes to oncogenesis, immune disorders, and developmental syndromes. Oncogenic mutations in proteins like SRC, PIK3R1, and aberrant fusion proteins involving SH2 domains (identified in clinical sequencing at Mayo Clinic and Memorial Sloan Kettering Cancer Center) drive cancers profiled by consortia including The Cancer Genome Atlas and International Cancer Genome Consortium. SH2 domain mutations in PTPN11 are implicated in Noonan syndrome and juvenile myelomonocytic leukemia, with clinical investigations at Boston Children's Hospital and St. Jude Children's Research Hospital. Infectious disease studies at Centers for Disease Control and Prevention have explored pathogen effectors targeting SH2 interactions, and translational programs at Novartis and Roche assess biomarkers based on SH2 signaling.
Detection and characterization of SH2 interactions employ phosphopeptide arrays developed at Stanford University and Broad Institute, X-ray crystallography at Argonne National Laboratory, NMR spectroscopy in facilities at Riken, and mass spectrometry-based phosphoproteomics advanced at Proteome Sciences and European Proteomics Association. Yeast two-hybrid screens at University of Edinburgh and affinity purification-mass spectrometry pipelines at Max Planck Institute for Biochemistry map SH2 interaction networks. Surface plasmon resonance technologies from GE Healthcare and biolayer interferometry have been used to quantify binding kinetics, while live-cell imaging at Rockefeller University and single-molecule methods at University of Oxford visualize dynamic recruitment.
Comparative genomics initiatives at National Human Genome Research Institute and Broad Institute reveal SH2 domain expansions in metazoans and limited representation in fungi and plants, with evolutionary analyses by groups at Sanger Institute and European Bioinformatics Institute. Paralogous families include the Src homology-containing kinases and adaptor proteins such as GRB2 and CRK, diversified by gene duplication events cataloged by consortia including Ensembl and UniProt. Sequence-based phylogenies from researchers at University of Basel and University of Geneva trace lineage-specific innovations and conservation of phosphotyrosine-binding pockets.
Drug discovery programs at pharmaceutical companies including Pfizer, GlaxoSmithKline, Novartis, AstraZeneca, and biotech firms like Genentech have pursued inhibitors and modulators that disrupt SH2-mediated interactions, using fragment-based lead discovery at ISIS Pharmaceuticals and structure-guided design informed by crystallography at Diamond Light Source. Clinical trials coordinated by institutions such as National Cancer Institute and European Medicines Agency evaluate small molecules, stapled peptides, and biologics that target SH2-dependent signaling in cancers and immunological diseases. Resistance mechanisms and combination strategies are under study at University of California, San Diego and Fred Hutchinson Cancer Research Center.
Category:Protein domains